Syntara

• Contract Research Organisation (CRO) Services: Syntara operates as a CRO, offering its services to other companies in the biotechnology and pharmaceutical sectors. This likely encompasses various aspects of drug development, from early-stage research and development to larger scale manufacturing support.

• Focus on Biotherapeutics: Their primary concentration seems to be on biopharmaceuticals, which includes a wide range of therapeutic agents such as monoclonal antibodies, recombinant proteins, and other biologics.

• Commitment to Quality: The website highlights a dedication to delivering high-quality services and maintaining rigorous quality standards, essential within the regulated biopharmaceutical industry.

• Australian Based: Syntara is clearly identified as an Australian company, suggesting a commitment to supporting the domestic biotechnology ecosystem. This likely involves collaboration with Australian research institutions and potentially benefiting from government support initiatives.

• Limited Public Information: Detailed information on their client list, specific technologies employed, or the size of their operations remains undisclosed on their publicly accessible website.

In summary: Syntara presents itself as a key player in the Australian biopharmaceutical landscape, providing crucial contract research services to support the development and manufacture of biotherapeutics. While specific details of their operations are limited publicly, their commitment to quality and focus on biopharmaceutical development suggests a significant role within the Australian biotech industry.